{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:54:55Z","timestamp":1792068895542,"version":"4.4.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bmc.2026.118804","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:40:46Z","timestamp":1788676846000},"page":"118804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Structural optimization of 2-(2-aminopyridin-4-yl)-N-(3-carbamoyl-1H-pyrazol-4-yl)-1,3-oxazole-4-carboxamide derivatives as potent interleukin-1 receptor-associated kinase 4 inhibitors"],"prefix":"10.1016","volume":"143","author":[{"given":"Hiroshi","family":"Inami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Usuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Hayashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2026.118804_bb0005","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.1073\/pnas.082100399","article-title":"IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase","volume":"99","author":"Li","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmc.2026.118804_bb0010","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nature736","article-title":"Severe impairment of interleukin-1 and toll-like receptor signalling in mice lacking IRAK-4","volume":"416","author":"Suzuki","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2026.118804_bb0015","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/j.bcp.2010.06.020","article-title":"The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling","volume":"80","author":"Flannery","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmc.2026.118804_bb0020","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1124\/pr.109.001073","article-title":"Therapeutic targeting of toll-like receptors for infectious and inflammatory diseases and cancer","volume":"61","author":"O\u02bcNeill","year":"2009","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bmc.2026.118804_bb0025","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2026.118804_bb0030","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1084\/jem.20061523","article-title":"Essential role of IRAK-4 protein and its kinase activity in toll-like receptor\u2013mediated immune responses but not in TCR signaling","volume":"204","author":"Kawagoe","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.bmc.2026.118804_bb0035","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1084\/jem.20061825","article-title":"A critical role for IRAK4 kinase activity in toll-like receptor\u2013mediated innate immunity","volume":"204","author":"Kim","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.bmc.2026.118804_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102461","article-title":"IRAK family in inflammatory autoimmune diseases","volume":"19","author":"Su","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.bmc.2026.118804_bb0045","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/MOH.0000000000000693","article-title":"IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies","volume":"29","author":"Bennett","year":"2022","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.bmc.2026.118804_bb0050","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1021\/jm5016044","article-title":"Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders","volume":"58","author":"Chaudhary","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118804_bb0055","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/bs.pmch.2016.11.004","article-title":"Small molecule inhibition of interleukin-1 receptor-associated kinase 4 (IRAK4)","volume":"56","author":"Genung","year":"2017","journal-title":"Prog Med Chem"},{"key":"10.1016\/j.bmc.2026.118804_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115606","article-title":"The recent advance of interleukin-1 receptor associated kinase 4 inhibitors for the treatment of inflammation and related diseases","volume":"258","author":"Bai","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118804_bb0065","doi-asserted-by":"crossref","first-page":"5521","DOI":"10.1021\/acs.jmedchem.7b00231","volume":"60","author":"Lee","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118804_bb0070","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1021\/acs.jmedchem.3c01714","article-title":"Discovery of IRAK4 inhibitors BAY1834845 (zabedosertib) and BAY1830839","volume":"67","author":"Bothe","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118804_bb0075","doi-asserted-by":"crossref","first-page":"10619","DOI":"10.1021\/acs.jmedchem.5c00463","article-title":"Discovery of edecesertib (GS-5718): a potent, selective inhibitor of IRAK4","volume":"68","author":"Ammann","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118804_bb0080","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1021\/acsmedchemlett.0c00255","article-title":"Discovery of CA-4948, an orally bioavailable IRAK4 inhibitor for treatment of hematologic malignancies","volume":"11","author":"Gummadi","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2026.118804_bb0085","doi-asserted-by":"crossref","first-page":"18022","DOI":"10.1021\/acs.jmedchem.4c01305","article-title":"Discovery of KT-474\u2014a potent, selective, and orally bioavailable IRAK4 degrader for the treatment of autoimmune diseases","volume":"67","author":"Zheng","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118804_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117302","article-title":"Design, synthesis, and pharmacological evaluation of N-(3-carbamoyl-1H-pyrazol-4-yl)-1,3-oxazole-4-carboxamide derivatives as interleukin-1 receptor-associated kinase 4 inhibitors with reduced potential for cytochrome P450 1A2 induction","volume":"87","author":"Inami","year":"2023","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2026.118804_bb0095","first-page":"S390","article-title":"Anti-inflammatory profile of AS2444697, a novel interleukin-1 receptor-associated kinase-4 inhibitor","volume":"63","author":"Imanishi","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bmc.2026.118804_bb0100","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s00210-014-1023-z","article-title":"Renoprotective effects of novel interleukin-1 receptor-associated kinase 4 inhibitor AS2444697 through anti-inflammatory action in 5\/6 nephrectomized rats","volume":"387","author":"Kondo","year":"2014","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"10.1016\/j.bmc.2026.118804_bb0105","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00210-020-01816-2","article-title":"Therapeutic effects of interleukin-1 receptor-associated kinase 4 inhibitor AS2444697 on diabetic nephropathy in type 2 diabetic mice","volume":"393","author":"Kondo","year":"2020","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"10.1016\/j.bmc.2026.118804_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118333","article-title":"Generation of a potent & selective series of IRAK4 inhibitors based on a structure based, hybridization approach","volume":"131","author":"Terstiege","year":"2025","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2026.118804_bb0115","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2174\/1568026043387188","article-title":"Cytochromes P450 in the bioactivation of chemicals","volume":"4","author":"Ioannides","year":"2004","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bmc.2026.118804_bb0120","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1021\/ol005777b","article-title":"Synthesis of functionalized oxazolines and oxazoles with DAST and Deoxo-fluor","volume":"2","author":"Phillips","year":"2000","journal-title":"Org Lett"},{"key":"10.1016\/j.bmc.2026.118804_bb0125","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0960-894X(01)00174-3","article-title":"Adamantylaminopyrimidines and -pyridines are potent inducers of tumor necrosis factor-\u03b1","volume":"11","author":"Kazimierczuk","year":"2001","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2026.118804_bb0130","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1021\/jo070189y","article-title":"A general and efficient 2-amination of pyridines and quinolines","volume":"72","author":"Yin","year":"2007","journal-title":"J Org Chem"},{"key":"10.1016\/j.bmc.2026.118804_bb0135","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1021\/jo00066a018","article-title":"Bicyclo[3.2.2]non-1-ene: matrix isolation and spectroscopic characterization of a moderately strained bridgehead olefin","volume":"58","author":"Gudipati","year":"1993","journal-title":"J Org Chem"},{"key":"10.1016\/j.bmc.2026.118804_bb0140","doi-asserted-by":"crossref","first-page":"6527","DOI":"10.1016\/j.tet.2013.05.004","article-title":"Chemo-enzymatic enantioconvergent approach toward ethyl shikimate from ethyl 5-hydroxy-3,4-isopropylidenedioxycyclohex-1-enecarboxylate","volume":"69","author":"Yamashita","year":"2013","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bmc.2026.118804_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115453","article-title":"Design, synthesis and pharmacological evaluation of 2,3-dihydrobenzofuran IRAK4 inhibitors for the treatment of diffuse large B-cell lymphoma","volume":"256","author":"Chen","year":"2023","journal-title":"Eur J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626002609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626002609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:36:32Z","timestamp":1792067792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626002609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":29,"alternative-id":["S0968089626002609"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118804","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural optimization of 2-(2-aminopyridin-4-yl)-N-(3-carbamoyl-1H-pyrazol-4-yl)-1,3-oxazole-4-carboxamide derivatives as potent interleukin-1 receptor-associated kinase 4 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118804","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118804"}}